The inspection was conducted from 25th April 2024 to 3rd May 2024. The inspection closed with 7 observations.

'The observations are procedural in nature and will be responded to within the stipulated time,” Aurobindo Pharma said in a statement.

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

The drug maker reported 90.58% jump in consolidated net profit to Rs 936.29 crore on 13.82% rise in revenue from operations to Rs 7,271.23 crore in Q3 FY24 over Q3 FY23.

The scrip had lost 0.10% to end at Rs 1152.70 on the BSE on Friday.